- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03003078
A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane (PanCO)
An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Study Participants With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With FOLFIRINOX or Gemcitabine+Nab-paclitaxel Chemotherapies
To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy regulatory requirements.
The clinical investigation will be conducted at approximately 15 sites in Australia, the United Kingdom and Europe (Belgium) involving 40 patients.
Study Overview
Status
Intervention / Treatment
Detailed Description
Detailed description
The purpose of this research study is to investigate the safety of an active implantable (radiological) medical device OncoSil™, when implanted into patients with pancreatic cancer, in conjunction with Standard of Care (SOC) chemotherapy. OncoSil™, is an experimental treatment and carries the active treatment "radioactive Phosphorous (32P)" inside inactive silicon particles. Once implanted, the OncoSil™ Microparticles will stay in the tumour permanently. The purpose of OncoSil™, is to deliver the action of 32P directly into a targeted tumour to destroy cancer cells.
40 Patients will be taking part in a single arm open label research study - which means that everyone in the research study will receive the investigational treatment OncoSil™, plus their prescribed standard chemotherapy regimen which will be either; FOLFIRINOX (FOLFIRINOX is the name of a combination of chemotherapy drugs used to treat advanced cancer of the pancreas) or gemcitabine + nab-paclitaxel (Abraxane).
Endpoints: Primary Endpoint:
• Safety and Tolerability
Secondary Endpoints:
Efficacy
- Local Disease Control Rate at 16 weeks
- Local Progression Free Survival (LPFS), within the pancreas
- Progression Free Survival (PFS), all sites
- Overall Survival (OS)
- Body weight
- Impaired function
- Pain Scores
The screening period will be performed within a 2 week period, followed by a treatment period of investigational visits which will occur weekly from Day 0 (Visit 1) until week 12, then 4 weeks later at week 16, and then at 8-weekly intervals until study participants reach documented progression of disease criteria for both LPFS and PFS which marks the end of study participation i.e. EOS visit.
An 8-weekly review of medical records will be used to monitor possible device or late radiation related adverse events, and oncology treatments/procedures administered for up to 12 months post OncoSil™ implantation.
Overall survival will be conducted via 8-weekly medical record reviews until study participant death, or until 104 weeks post the last study participant enrolled.
Activity (Dose): The intended average absorbed radiation dose per treated tumour is 100 Gy (+20%).
Risks associated with OncoSil™ and/or implantation procedure
The following adverse events, considered to have a causal relationship with OncoSil™ or procedure, were recorded during previous clinical studies:
- Procedure-related pain
- Abdominal pain and discomfort
- Lethargy
- Fever
- Nausea and vomiting
- Abnormal liver function tests
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New South Wales
-
Corrimal, New South Wales, Australia, 2518
- Corrimal Cancer Care Clinic, 20-22 Underwood St
-
St Leonards, New South Wales, Australia, 2065
- Department of Medical Oncology, Royal North Shore Hospital
-
Sydney, New South Wales, Australia, 2010
- The Kinghorn Cancer Centre, St Vincent's Hospital
-
Westmead, New South Wales, Australia, 2145
- The Crown Princess Mary Cancer Centre, Westmead Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Department of Gastroenterology and Hepatology, Royal Adelaide Hospital
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Institute for Breathing and Sleep -Bowen CentreAustin Health
-
Melbourne, Victoria, Australia, 3165
- Monash Cancer Centre
-
-
-
-
-
Bruxelles, Belgium
- Institut Jules Bordet
-
-
-
-
-
London, United Kingdom, W12 0HS
- Hammersmith Hospital
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
- Cambridge Cancer Trials Centre, Addenbrooke's Hospital
-
-
East Midlands
-
Leicester, East Midlands, United Kingdom, LEI 5WW
- Leicester Royal Infirmary
-
-
Greater London
-
London, Greater London, United Kingdom, SE19RT
- Guy's and St Thomas' NHS Foundation Trust,
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically proven adenocarcinoma of the pancreas.
- Unresectable locally advanced pancreatic carcinoma. Patients with technically resectable tumours (T1-T3) will also be eligible, if they are deemed unresectable due to medical comorbidities or refusal of surgery.
- Pancreatic target tumour diameter of ≥ 2.0 cm (shortest axis) to ≤ 6.0 cm (longest axis), as qualified by the central reading centre.
- An ECOG Performance Status of 0 to 1 and Karnofsky Performance Status of 80 - 100.
- Study participants ≥ 18 years of age at screening.
- To commence first-line standard FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapy (per standard of care according to the approved prescribing schedule), within 14 days post enrolment, with OncoSil™ implantation to occur during the fourth (4th) week of the first chemotherapy cycle.
- Provide signed Informed Consent.
- Willing and able to complete study procedures within the study timelines.
- Adequate renal function: serum creatinine less than 1.5 x upper limit of normal (ULN).
Adequate liver function: serum liver transaminases ≤ 3 × ULN and serum bilirubin
≤ 1.5 × ULN*.
*For study participants with recent biliary obstruction treated by drainage (e.g. stent), serum bilirubin of > 1.5 x ULN will be accepted for study entry provided that serial levels demonstrate clear improvement. In addition, chemotherapy should not be commenced until serum bilirubin is ≤ 1.5 × ULN.
- Adequate bone marrow function: white blood cells (WBCs) ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, haemoglobin ≥ 9 g/dL, and platelets ≥ 100,000/mm3.
- Life expectancy of at least 3 months at the time of screening as judged by the investigator.
- Treated with or eligible to commence prophylactic treatment with a proton-pump inhibitor prior to implantation, and to continue to receive treatment for at least 6 months post implantation.
- Not pregnant, and if of childbearing potential, agrees to use adequate birth control (hormonal or barrier method of birth control or abstinence) prior to study entry and during the study and agrees not to donate sperm or ova, for the duration of the study and 12 months post implantation of the investigational device.
Exclusion Criteria
- Evidence of distant metastases, based on review of baseline CT scan, as determined by the central reading centre.
- More than one primary lesion.
- Any prior radiotherapy or chemotherapy for pancreatic cancer.
- Use of other investigational agent at the time of screening, or within 30 days or five half-lives of Screening Visit 1, whichever is longer.
- Pregnant or lactating.
In the opinion of the investigator, EUS directed implantation posing undue study participant risk. This includes:
- where previous EUS-FNA was considered technically too difficult to perform;
- imaging demonstrates multiple collateral vessels surrounding or adjacent to the target tumour within the pancreas;
- presence (or significant risk) of varices near to the target tumour. Note: The feasibility of implantation of the target tumour and assessment of risk can be conducted at any time between Screening Visit 1 and the implantation date. A study participant should be considered for withdrawal prior to and including at the time of OncoSil™ treatment, if any of the above risk features become apparent following subject screening and/or enrolment.
- History of malignancy, treated or untreated, within the past five years whether or not there is evidence of local recurrence or metastases, with the exception of basal cell carcinoma of the skin and cervical carcinoma in situ.
- Evidence of radiographic invasion into stomach, duodenum or peritoneum (if not certain confirmation must be obtained prior to enrolment).
- A known allergy or history of hypersensitivity to silicon, phosphorous or any of the OncoSil™ components.
- Any other health condition that would preclude participation in the study in the judgment of the investigator.
Note: T1-T3 is determined as per The American Joint Committee on Cancer (AJCC) tumor/node/metastasis (TNM) classification and staging system for pancreatic cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: OncoSil™ plus SOC Chemotherapy
OncoSil™ implanted with concurrent Standard of care Chemotherapy - either FOLFIRINOX or gemcitabine + Abraxane.
|
The implantation of OncoSil™
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety / Tolerability of Device according to CTCAE V4.0
Time Frame: Collected from the of signed informed consent until patient death or 104 weeks post last patient enrollment date, whichever is sooner
|
as determined by the number of treatment emergent adverse events (TEAEs) evaluated
|
Collected from the of signed informed consent until patient death or 104 weeks post last patient enrollment date, whichever is sooner
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local Progression free survival within the pancreas
Time Frame: Assessed from Baseline through to first confirmed CT documentation of local progression within the pancreas, an average of 12 months.
|
Central reader review of CT changes throughout study enrolment
|
Assessed from Baseline through to first confirmed CT documentation of local progression within the pancreas, an average of 12 months.
|
Progression free survival - entire body
Time Frame: Assessed from Baseline through to EOS visit - an average of 12 months.
|
Central reader review of CT changes throughout study enrolment
|
Assessed from Baseline through to EOS visit - an average of 12 months.
|
Overall survival
Time Frame: 104 weeks post last patient first study visit
|
Time to participant death from enrolment
|
104 weeks post last patient first study visit
|
Body weight
Time Frame: Assessed from Baseline through to EOS visit, an average of 12 months.
|
Recorded body weight at each study visit
|
Assessed from Baseline through to EOS visit, an average of 12 months.
|
Impaired function
Time Frame: Frame: Measured at each study visit for the duration of the study, an average of 12 months
|
as measured by changes in the Karnofsky Performance Status from screening
|
Frame: Measured at each study visit for the duration of the study, an average of 12 months
|
Pain Scores
Time Frame: Measured at each study visit for the duration of the study, an average of 12 months
|
As measured at each study visit using the Numerical Rating scale (NRS)
|
Measured at each study visit for the duration of the study, an average of 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
tumour response
Time Frame: Baseline measure from screening period, compared to Week 8 CT result, and then to 8 weekly CT results until local progression is determined, an average of 12 months.
|
as demonstrated by target tumour volumetric change (measured by a central reading centre)
|
Baseline measure from screening period, compared to Week 8 CT result, and then to 8 weekly CT results until local progression is determined, an average of 12 months.
|
tumour response
Time Frame: As assessed at Week 12 study visit compared to Baseline assessment completed during screening period
|
as demonstrated by target tumour FDG-PET parameters (measured by a central reading centre)
|
As assessed at Week 12 study visit compared to Baseline assessment completed during screening period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul J Ross, MRCP MBBS, Guy's and St Thomas' NHS Foundation Trust
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONC01P03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unresectable Locally Advanced Pancreatic Carcinoma
-
Shanghai Runshi Pharmaceutical Technology Co., LtdJilin Provincial Tumor HospitalRecruitingLocally Advanced Unresectable CarcinomaChina
-
Impact Biotech LtdImpact biotech Ltd.Not yet recruitingLocally Advanced Unresectable Pancreatic Adenocarcinoma
-
National Cancer Institute (NCI)SuspendedStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic AdenocarcinomaUnited States
-
Roswell Park Cancer InstituteIpsenActive, not recruitingUnresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditionsUnited States
-
Faeth TherapeuticsRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic AdenocarcinomaUnited States
-
OncoSil Medical LimitedCompletedUnresectable Locally Advanced Pancreatic CarcinomaUnited States
-
FutureGen Biopharmaceutical (Beijing) Co., LtdRecruitingLocally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaChina
-
University Hospital Hradec KraloveBristol-Myers Squibb; GCP-Service International s.r.o.CompletedLocally Advanced Unresectable Pancreatic AdenocarcinomaCzechia
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States
Clinical Trials on OncoSil™
-
OncoSil Medical LimitedCompletedUnresectable Locally Advanced Pancreatic CarcinomaUnited States
-
Chinese University of Hong KongRecruitingPancreatic Cancer | Endoscopic UltrasoundHong Kong
-
OncoSil Medical LimitedRecruitingLocally Advanced Pancreatic CancerSpain, Belgium, United Kingdom, Italy, Australia
-
BaroNova, Inc.Completed
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUnknownBrain Damage, Chronic | Cerebellar Cognitive Affective Syndrome | Cerebellar Mutism
-
Asklepios Kliniken Hamburg GmbHUniversity of KielCompletedAirway Management | Laryngeal Mask Airway | Fibreoptic Intubation
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalUnknownTemporal Lobe Epilepsy
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...RecruitingHydrocephalus | Hydrocephalus, CommunicatingArgentina
-
Medtronic CardiovascularActive, not recruitingAortic AneurysmGermany, New Zealand, United States, Netherlands, Switzerland, United Kingdom, Spain, Australia, Italy, Sweden, France, Austria, Slovakia
-
Gülçin Özalp GerçekerCompletedCatheter Complications | Catheter LeakageTurkey